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Abstract 
Purpose: To investigate the ameliorative effect of daidzin (DZ) on diabetes in streptozotocin (STZ)-
induced diabetic Institute of Cancer Research (ICR) mice, with a view to determining its usefulness in 
the treatment of diabetes. 
Methods: The effect of DZ (100, 200 and 400 mg/kg) on blood glucose was investigated in both normal 
and STZ-induced diabetic mice with glibenclamide (3 mg/kg) and metformin (400 mg/kg) as positive 
control, respectively. Serum or hepatic levels of lipid, proinflammatory factors, malondialdehyde (MDA) 
and superoxide dismutase (SOD) were measured. Glucosidase activity assay and glucose uptake by 
C2C12 myotubes were performed in vitro and the expression of glucose transporter 4 (GLUT4) in 
C2C12 cells was determined by western blot. 
Results: DZ (200 and 400 mg/kg) did not decrease fasting blood glucose in normal mice but inhibited 
starch-induced postprandial glycemia. Oral administration of 400 mg/kg of DZ for 14 days significantly 
decreased mouse blood glucose (p < 0.01), as well as serum total cholesterol (TC, p < 0.01), 
triglycerides (TG, p < 0.01), low-density lipoprotein cholesterol (LDL-c, p < 0.01) levels in STZ-induced 
hyperglycemic mice and improved oral glucose tolerance. The serum and hepatic activity of SOD was 
enhanced (p < 0.01 and p < 0.001, respectively) while MDA level decreased (p < 0.001). Blood 
concentrations of interleukin-6 (IL-6, p < 0.001), tumor necrosis factor α (TNF-α, p < 0.01), monocyte 
chemotactic protein 1 (MCP-1, p < 0.01) were also significantly reduced. In vitro glucosidase activity 
results showed that DZ inhibited α-glucosidase with IC50 values of 82, 98 and 389 μg/mL for α-
glucosidase from S. cerevisiae, Rhizopus sp. and rat intestines, respectively. It also stimulated glucose 
uptake and GLUT4 membrane translocation in C2C12 myotubes at 20 μM (p < 0.05).  
Conclusion: Oral administration of DZ is effective in alleviating diabetic hyperglycemia, dyslipidemia 
and inflammation. Inhibition of α-glucosidase and stimulation of glucose consumption by muscles may 
account for its inhibitory effect on blood glucose. 
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Diabetes mellitus (DM) is becoming a most 
serious threat to human health with an incidence 
of 8.7 % (about 387 million patients) throughout 
the world, imposing a heavy burden on national 
healthcare systems, particularly in developing 
countries [1,2]. In the DM state, insulin activity is 
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reduced, resulting in decreased insulin-
stimulated glucose uptake. Simultaneously, 
abnormal metabolism of fuel nutrients [3], 
disordered activities of antioxidant enzymes [4] 
and increased inflammation [5] lead to a 
pronounced oxidative stress, which is 
characterized by increased malondialdehyde 
(MDA) level and decreased activities of 
antioxidant enzymes such as superoxide 
dismutase (SOD). In the current circumstances, 
a search for an antidiabetic herbal product with 
fewer side effects has gained considerable 
importance in the medical field [6]. Daidzin (DZ) 
is a major isoflavone glycoside obtained from 
Puerariae radix, a well-known Chinese herbal 
medicine for the treatment of diabetes and 
cardiovascular diseases [7-9]. Various 
pharmacological activities of DZ have been 
reported including antioxidant [10], estrogenic 
[11] and anti-inflammatory [12]. The effect of DZ 
on blood glucose remains controversial. Choi et 
al [13] reported the inhibitive effect of DZ on 
yeast α-glucosidase, suggesting that DZ may be 
an alternative to acarbose for the treatment of 
diabetes. However, Meezan et al [14] reported 
that intraperitoneal injection of DZ impaired 
glucose tolerance in ob/ob diabetic mice. 
Recently, Zang et al [15] demonstrated that the 
mixture of DZ and glycitin can efficiently 
decrease blood glucose and serum HbA1c in 
hyperglycemic mice. Although the mixture of DZ 
and glycitin were effective in the treatment of 
DM, the exact role of DZ was not distinguished in 
their report.  
 
In the present work, we investigated the effects 
of oral administration of DZ on diabetes-related 
hyperglycemia, dyslipidemia, perioxidative state, 
inflammation in streptozotocin (STZ)-induced, to 
demonstrate the potential utility of DZ in the 






Daidzin (DZ), with a purity of 99.6 % as 
determined by HPLC, was purchased from 
Forever-biotech Co. Ltd (Shanghai, China). 
Dulbecco’s modified Eagle’s medium (DMEM), 




from Saccharomyces cerevisiae, rat intestinal 
acetone powder were procured from Sigma-
Aldrich, Inc. (St Louis, USA). α-Glucosidase from 
Rhizopus sp. was sourced from Gold Wheat 
Biotech, Inc. (Shanghai, China). Specific kits for 
glucose, total cholesterol (TC), triglyceride (TG), 
low-density lipoprotein cholesterol (LDL-c), high-
density lipoprotein cholesterol (HDL-c), 
malondialdehyde (MDA), interleukin-6 (IL-6), 
tumor necrosis factor α (TNF-α), monocyte 
chemotactic protein 1 (MCP-1), and activity of 
superoxide dismutase (SOD) were purchased 
from Jian Cheng Biotechnology Company 
(Nanjing, China). Antibodies against Glucose 
transporter type 4 (GLUT4) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were 




Male Institute of Cancer Research (ICR) mice 
(20 - 22 g each) were obtained from the Institute 
of Laboratory Animal Science, Chinese Academy 
of Medical Sciences, Beijing, China. The study 
was carried out according to the “Principles of 
Laboratory Animal Care” [16] and approved by 
Animal Ethics Committee of Zhengzhou 
University (no. 2014090210). A standard pellet 
diet and water were given ad libitum. Animals 
were housed under a constant 12-h light and 
dark cycle and in an environment of 21 - 23 °C. 
 
To test the effect of DZ in normal mice, the 
animals were randomly divided into five groups 
with eight mice in each group. Mice were daily 
treated with glibenclamide (3 mg/kg) or DZ (as 
indicated) orally for 14 days. Control group was 
given equal volume of distilled water. At the end 
the experiment, animals were fasted for 4 hours 
and the fasting blood glucose levels were 
evaluated. For postprandial glycemia test, 
animals were fasted for 4 h then treated with the 
corresponding agents orally. After another 15 
min, each mouse was given 4 g/kg of starch 
(p.o.) [17]. Blood glucose levels at 0, 1 and 2 h 
after starch administration were determined by a 
blood glucose meter (Roche, ACCU-CHEK 
Active). Area under the curve was calculated as 
previously reported [17]. 
 
Next, male ICR mice were rendered diabetic by 
intraperitoneal injection of STZ (80 mg/kg)[18] in 
citrate buffer, pH 4.5. Five days later, the animals 
were fasted for 8 h, blood samples taken from 
their tail vein and the plasma glucose 
concentration was measured. Animals with blood 
glucose concentration above 12 mM were 
selected for the study. 
 
STZ-induced diabetic mice were divided into 
groups randomly with 8 mice in each group. 
Animals were daily treated with metformin (400 
mg/kg) [19] or DZ (100, 200 and 400 mg/kg) 
orally for 14 days. Control group was given an 
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equal volume of distilled water. At the end of the 
experiments and after fasted for 4 h, animals 
were euthanized and the blood and liver samples 
was obtained for the estimation of various 
biochemical parameters by specific kits following 
the manufacturer’s instructions. 
 
For oral glucose tolerance test (OGTT), the 
animals were fasted for 4 h then treated with 
corresponding agents orally. After another 2 h, 
each mouse was given 4 g/kg of glucose (p.o.) 
[20]. Blood glucose levels were determined at 0, 
0.5, 1, 1.5 and 2 h after glucose administration 




C2C12 cells, originating from the American Type 
Culture Collection (ATCC) (Manassas, VA, USA), 
were obtained from the Peking Union Medical 
College. C2C12 myoblasts were cultured in 
DMEM supplemented with 10 % FBS at 37 oC 
and 5 % CO2. To induce differentiation, media 
was replaced with DMEM containing 2 % horse 
serum (Sigma-Aldrich, Inc., St Louis, USA) 
whenever the cells reached confluence. 
Experiments were performed in differentiated 
C2C12 myotubes 5 days after differentiation was 
induced. 
 
Glucose uptake assay 
 
Glucose uptake assay was performed as 
previously reported [21]. Briefly, differentiated 
C2C12 myotubes were incubated with the 
serum-free DMEM containing the fluorescent 
glucose analog 2-NBDG (10 μM) and DZ (1, 5 or 
10 μM) in the presence or absence of insulin 
(100 nM). After incubation for 12 h, medium was 
removed and cells were washed with phosphate-
buffered saline (PBS) twice. Cells were scraped 
out in 1 mL of PBS and transferred into 5 mL 
polystyrene round-bottom tubes (BD Falcon) and 
kept at 4 °C. The amount of 2-NBDG taken up by 
the cells was measured by determining the 
fluorescence intensities at Ex/Em=475 nm/550 
nm using a Tecan Infinite M1000Pro Microplate 




GLUT4 membrane translocation in C2C12 
myotubes was analyzed by western blot. Cell 
membrane preparation and western blot 
procedure were performed as previously 
reported [6]. GAPDH was used as internal 
reference. The immunoreactive bands were 
quantified using ImageJ 4.1 software (NIH, 
Bethesda, USA). 
 
α-Glucosidase inhibition assay 
 
Inhibition of α-glucosidase and α-amylase 
activities were performed according to the 
chromogenic method described previously [22], 
using PNPG as substrate. Acarbose was used as 
positive control. The inhibitory activity was 
calculated as in Eq 1. 
 
Inhibition = {(Ac – At)/Ac}100 ……………… (1) 
 
where Ac and At are the absorbance of control 




The results are expressed as mean ± standard 
error of the mean (SEM). The data were 
analyzed by one-way analysis of variance 
(ANOVA) using SPSS 13.0 software. Significant 




Effect of daidzin in normal mice 
 
The effect of daidzin (DZ) on blood glucose was 
first assessed in normal mice. As shown in 
Figure 1A, DZ did not decrease fasting blood 
glucose levels in normal mice. This indicates that 
DZ may not stimulate insulin secretion and hence 
has a low risk of inducing hypoglycemia. In 
contrast, treatment with DZ (200 and 400 mg/kg) 
significantly inhibited the increase of serum 
glucose levels after oral administration of starch 
(p < 0.05) (Figure 1B and 1C), suggesting that 
DZ is effective in preventing postprandial 
glycemia. 
 
Effect of daidzin in diabetic mice 
 
We further evaluated the antihyperglycemic 
effect of DZ in streptozotocin (STZ)-induced 
diabetic mice. Oral administration of DZ (200 and 
400 mg/kg) decreased fasting blood glucose (p < 
0.05 and p < 0.01, respectively) (Figure 2A) and 
improved glucose tolerance in oral glucose 
tolerance test (Figure 2B and C). The potency of 
DZ at 400 mg/kg was significant but weaker than 
metformin (400 mg/kg), a popular antidiabetic 
medicine. These results suggested that DZ can 
decrease blood glucose levels and improve 
glucose tolerance in diabetic animals. 
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Figure 1: Effect of daidzin (DZ) on blood glucose levels in normal mice. (A) Fasting blood glucose. (B) 
Postprandial glycemia. (C) Area under the curve of postprandial blood glucose concentration. Values represent 




Figure 2: Effect of daidzin (DZ) on blood glucose levels in diabetic mice. (A) Fasting blood glucose. (B) Oral 
glucose tolerance test (OGTT). (C) Area under the curve of OGTT. Values represent mean ± SEM (n = 8); *p < 
0.05, **p < 0.01, ***p < 0.001 versus DM group. NM, diabetic control; Met, metformin; DZ, daizdin 
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Daidzin effect on blood lipid of diabetic mice 
 
As shown in Figure 3, treatment with DZ dose-
dependently reduced the levels of serum TC, TG 
and LDL-c. At the optimal dose (400 mg/kg), DZ 
decreased serum concentration of TC, TG and 
LDL-c by 23.81, 29.84 and 21.43 %, respectively, 
which is lesser than the effect of metformin (400 
mg/kg). The level of serum HDL-c was elevated 
by metformin but not affected by DZ (Figure 3). 
 
Daidzin improves perioxidative states in 
diabetic mice 
 
Treatment with DZ (100, 200 and 400 mg/kg) 
dose-dependently increased SOD activity and 
decreased the concentration of MDA in serum 
and liver (Figure 4). The antioxidative effect of 
DZ at 400 mg/kg was more pronounced than that 
of metformin (400 mg/kg). 
 
Daidzin alleviates inflammation in diabetic 
mice 
 
Treatment with DZ significantly decreased serum 
levels of interleukin-6 (IL-6), tumor necrosis 
factor α (TNF-α) and monocyte chemotactic 
protein 1 (MCP-1) (Figure 5), displaying potent 
anti-inflammatory effects. This observation is in 
accordance with previous reports [12,23]. The 
efficacy of DZ (200 and 400 mg/kg) in decreasing 
serum IL-6, TNF-α and MCP-1 was comparable 




Figure 3: Effect of daidzin (DZ) on serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein 
cholesterol (LDL-c) and high-density lipoprotein cholesterol in diabetic mice. Values represent mean ± SEM (n = 
8). *p < 0.05, **p<0.01 versus DM group. NM, diabetic control; Met, metformin; DZ, daizdin 
 
 
Figure 4: Effect of daidzin (DZ) on SOD activity and MDA concentration in diabetic mice. (A) Serum level (in 
U/mL for SOD, nmol/mL for MDA). (B) Liver level (in U/mg protein for SOD, nmol/mg protein for MDA). Values 
represent mean ± SEM (n = 8). **p < 0.01,  ***p < 0.001 versus DM group. NM, diabetic control; Met, metformin; 
DZ, daizdin 
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Figure 5: Effect of daidzin (DZ) on serum levels of IL-6 (A), TNF-α (B) and MCP-1 (C). Values represent mean ± 
SEM (n = 8). **p < 0.01,  ***p < 0.001 versus DM group. NM, diabetic control; Met, metformin; DZ, daizdin 
 
Daidzin stimulates glucose uptake and 
increases GLUT4 translocation in C2C12 
myotubes 
 
We also found that DZ activated glucose 
consumption in a dose-dependent manner in 
C2C12 myotubes. The effect of DZ on glucose 
uptake was assessed by NBD-glucose (2-NBDG) 
uptake assay. Treatment with DZ for 12 h 
increased 2-NBDG uptake by C2C12 myotubes 
in a dose-dependent manner (Figure 6A), 
suggesting a potent activity of DZ in stimulating 
glucose uptake by myotubes. In accordance with 
this finding, DZ largely increased GLUT4 
membrane translocation without significantly 




Figure 6: Effect of daidzin (DZ) on glucose uptake (A) and glucose transporter 4 (GLUT4) translocation in C2C12 
myotubes. (B) Western blot for total GLUT4, plasma membrane (PM) GLUT4 and GAPDH. (C) Quantitative 
results of B analysis by ImageJ 4.1 software. Values represent mean ± SEM. NBD-glucose (2-NBDG) was used 
as indicator. Insulin (100 nM) was used as positive control. The concentration of DZ was 1, 10 and 20 μM. 
Results are representative of 3 different experiments with n = 3 in each group. *p < 0.05, **p < 0.01. NC: negative 
control; Ins: insulin; DZ: daidzin; PM, plasma membrane 
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Daidzin inhibits the activity of α-glucosidase 
in vitro 
 
We further investigated the inhibitive effect of DZ 
on the activity of α-glucosidase in vitro. As shown 
in Figure 7, DZ inhibited the activity of α-
glucosidase in a dose-dependent manner. The 
IC50 values of DZ on α-glucosidase from S. 
cerevisiae, Rhizopus sp. and rat intestines were 
82 μg/mL, 98 μg/mL and 389 μg/mL, 
respectively. The in vitro effect of DZ on 
glucosidase was in good accordance to its 
inhibitive action on postprandial glycaemia in ICR 
mice (Figure 1B and C). These results suggest 
that DZ is an effective inhibitor of α-glucosidase 




Figure 7: Inhibitory activity of daidzin (DZ) on α-
glucosidase from S. cerevisiae (A), Rhizopus sp. (B) 
and rat intestines (C). 4-Nitrophenyl-α-
glucopyranoside (PNPG) was used as substrate. 
Acarbose was used as positive control. Data were 
plotted and the IC50 values were calculated by 
GraphPad Prism 4 software. Each value is expressed 




Daidzin (DZ) is a major isoflavone glycoside from 
Puerariae radix, a herb widely used in Chinese 
medicinal formulae for the treatment of diabetes 
[7-9]. Many pharmacological studies have been 
made on DZ but its effect on blood glucose 
remains controversial. In the present work, we 
demonstrated that oral administration of DZ is 
adequate in alleviating diabetes mellitus in STZ-
induced hyperglycemic mice.  
 
Treatment with DZ did not decrease fasting blood 
glucose in normal mice, suggesting that it has 
minimal effect on insulin secretion and thus 
possesses less risk for hypoglycemia. However, 
oral administration of DZ significantly decreased 
blood glucose and improved oral glucose 
tolerance in diabetic mice, showing an adequate 
effect on hyperglycemia. It also significantly 
decreased serum levels of TC, TG and LDL-c 
and slightly increased HDL-c levels. 
Simultaneously, diabetes-related inflammation 
and perioxidative state were largely alleviated by 
DZ. These results demonstrated that oral 
administration of DZ is beneficial for the 
treatment of hyperglycemia and diabetes-related 
syndromes.  
 
Meezan et al [14] found that intraperitoneal 
injection (i.p.) of DZ was detrimental for glucose 
homeostasis. This contradiction may be due to 
the different route by which DZ is administrated. 
As is well-known that isoflavones including DZ 
will undergo intensive metabolism in the gut of 
animals by gut microbiota after oral 
administration. Therefore, the actual bioactive 
compounds after DZ oral administration may 
likely be its metabolites other than DZ itself which 
will require further investigation. A recent study 
by Zang et al [15] demonstrated the positive role 
of the mixture of DZ and glycitin in decreasing 
blood glucose and serum HbA1c, which partly 
supported our findings. 
 
There are many approaches to efficiently 
decrease blood glucose level such as promoting 
insulin secretion [24], inhibiting glucose 
absorption [25], stimulating glucose uptake by 
tissues [26] and increasing insulin sensitivity [27]. 
Insulinotropic agents such as glibenclamide, 
stimulate insulin secretion and dramatically 
decrease blood glucose level in both normal and 
diabetic animals. Treatment with DZ showed no 
effects on blood glucose in normal mice. It is thus 
unlikely to promote insulin secretion. However, it 
significantly inhibited postprandial glycemia 
induced by starch, implying that DZ may be 
effective in inhibiting α-glycosidases and slowing 
glucose ingestion.  
 
α-Glucosidase data showed that DZ inhibited the 
activities of α-glucosidase of various origins in a 
dose-dependent manner, which was in good 
accordance with its in vivo action on postprandial 
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glycaemia, suggesting that DZ may inhibit 
hyperglycemia through at least in part inhibition 
of α-glucosidase. Promoting glucose uptake by 
muscles is another effective way to decrease 
blood glucose [8], in which GLUT4 plays a key 
role. Glucose uptake assay in C2C12 myotubes 
showed that DZ significantly promoted glucose 
consumption by myotubes and enhanced GLUT4 
membrane translocation as well, indicating that 
stimulating glucose uptake by muscles and 
enhancing GLUT4 membrane translocation may 





The findings of this work demonstrate that 
daidzin (DZ) can effectively decrease blood 
glucose and lipid, improve peroxidation and 
alleviate inflammation in diabetic animals. 
Stimulation of glucose consumption and 
inhibition of glucosidase may be involved in the 
blood glucose modulating effect of DZ. These 
results suggest that DZ is an effective regulator 
of glucose consumption in mice and may find 
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